Drug Overview:

Capecitabine serves as an oral prodrug formulation of 5-fluorouracil (5-FU), providing convenient outpatient chemotherapy for various solid tumors, including breast, colorectal, and gastric cancers. Widely adopted in adjuvant and palliative settings across US and European guidelines, it demonstrates comparable efficacy to continuous intravenous 5-FU infusions with superior patient convenience, reduced hospitalization needs, and preserved quality of life metrics.

Generic name: Capecitabine
US Brand names: Xeloda (150 mg, 500 mg film-coated tablets)
Drug Class: Fluoropyrimidine antimetabolite (oral chemotherapy prodrug)
Route of Administration: Oral (tablets taken whole)
FDA Approval Status: Initial approval April 30, 199,8 for metastatic breast cancer; expanded 2000-2006 for adjuvant/metastatic colorectal cancer and first-line gastric cancer combinations

What Is It and How Does It Work? (Mechanism of Action)

Capecitabine undergoes sequential tumor-selective enzymatic activation through a three-step biotransformation pathway, culminating in the generation of cytotoxic 5-FU preferentially within malignant tissues due to elevated thymidine phosphorylase expression. This site-specific conversion maximizes antitumor effects while minimizing exposure to healthy organs.

Hepatic carboxylesterase hydrolyzes capecitabine to inactive intermediate 5′-deoxy-5-fluorocytidine (5′-DFCR) primarily in the liver
Cytidine deaminase metabolizes 5′-DFCR to 5′-deoxy-5-fluorouridine (5′-DFUR) in both hepatic and tumor compartments
Thymidine phosphorylase (TP, 7-10x higher in tumors vs normal tissue) catalyzes the final conversion of 5′-DFUR to active 5-FU at cancer sites
Active 5-FU metabolite FdUMP forms a ternary complex with thymidylate synthase (TS) and 5,10-methylenetetrahydrofolate, irreversibly inhibiting dTMP synthesis essential for DNA replication (thymineless death)
5-FU triphosphate (FUTP) incorporates into nascent RNA, disrupting processing, maturation, and translation; FdUTP misincorporation into DNA triggers chain termination and futile excision repair

FDA-Approved Clinical Indications

Capecitabine holds broad FDA approvals as monotherapy or combination partner for major gastrointestinal and breast malignancies, with recent pharmacogenomic requirements mandating DPD deficiency screening to avert severe toxicity in 3-8% of patients carrying DPYD variants.

Oncological uses:

Adjuvant therapy for stage III (Dukes’ C) colon cancer following complete surgical resection
First-line metastatic colorectal cancer as monotherapy or combined with irinotecan (XELIRI) or oxaliplatin (XELOX/CAPOX)
Metastatic breast cancer after failure of anthracyclines and taxanes/paclitaxel (monotherapy or with docetaxel)
HER2-negative metastatic breast cancer previously treated with anthracycline, taxane, and trastuzumab in combination with lapatinib
First-line therapy for HER2-negative metastatic breast cancer in combination with docetaxel after prior anthracycline use
First-line metastatic or locally advanced gastric cancer in combination with platinum (cisplatin or oxaliplatin)

Non-oncological uses:

None approved

Dosage and Administration Protocols

Capecitabine employs body surface area (BSA)-based dosing on intermittent 14-days-on/7-days-off schedules within 21-day cycles, administered within 30 minutes post-meal to optimize bioavailability (AUC increases 20-30%). Dose banding to the nearest 150/500 mg tablet facilitates compliance.

Patient Population	Standard Dose	Frequency	Dose Adjustments
Adjuvant Stage III colon cancer	1250 mg/m²	BID days 1-14 every 21 days (8 cycles)	CrCl 30-50 mL/min: 75% dose (950 mg/m²); CrCl <30: contraindicated
Metastatic colorectal monotherapy	1250 mg/m²	BID days 1-14 every 21 days	Hepatic impairment mild: no adjustment; moderate/severe: start 75%, escalate
Metastatic breast monotherapy	2500 mg/m²/day	BID days 1-14 every 21 days	HFS Grade 2: hold until Grade 0/1, resume 50%; Grade 3: 25% permanent reduction
Breast cancer + docetaxel 75 mg/m²	2500 mg/m²/day capecitabine	BID cap days 1-14; docetaxel day 1 q21d	Diarrhea Grade 2+: hold both drugs until resolved
Gastric cancer + platinum	1000 mg/m² BID	Days 1-14 every 21 days	DPD partial deficiency: 50% starting dose with monitoring

Clinical Efficacy and Research Results

Long-term follow-up from pivotal X-ACT, NO16966, and ML17032 trials (2020-2025 analyses) plus real-world registries confirm capecitabine’s durable efficacy across indications, with convenient oral administration supporting elderly/frail populations.

Adjuvant colon cancer (X-ACT 10-year): Disease-free survival 64.0% capecitabine vs 59.1% Mayo 5-FU/LV (HR 0.88, p=0.04); superior safety profile
Metastatic colorectal XELOX (NO16966 update): Median PFS 8.0 months vs 6.4 months FOLFOX (HR 0.95); ORR 47%
Breast + lapatinib (EGF100151): Median PFS 6.1 vs 4.4 months (HR 0.57, p<0.001); OS 15.0 vs 13.5 months
Gastric platinum combinations (REAL-2): Median OS 11.7 months capecitabine+oxaliplatin vs 9.9 months 5-FU regimens (HR 0.86)

Safety Profile and Side Effects

Black Box Warning:

Capecitabine can cause severe, life-threatening, or fatal adverse reactions attributable to dihydropyrimidine dehydrogenase (DPD) deficiency, including diarrhea, dehydration, myelosuppression, neurotoxicity, and cardiotoxicity. Severe toxicity occurs in patients with DPD deficiency; test for DPYD variants prior to treatment.

Common Side Effects (>10%)

Hand-foot skin reaction (HFSR, 51-60%; prophylactic 10% urea/20% salicylic acid cream BID starting day 1, cotton socks/gloves, avoid hot water/friction)
Diarrhea (52%; loperamide 4 mg initial dose then 2 mg after each loose stool max 16 mg/day, hold Grade 3+, IV hydration if persistent)
Nausea (38%/vomiting 22%; ondansetron 8 mg BID, small frequent meals, ginger/dry crackers)
Fatigue (41%; moderate exercise, balanced nutrition, scheduled rest periods)
Abdominal pain/cramping (30%; antispasmodics like dicyclomine if severe)

Serious Adverse Events

Life-threatening diarrhea/dehydration (Grade 3/4 23%; immediate hospitalization for IV fluids 3L/day + octreotide 100-300 mcg TID if >8 stools/day)
Severe myelosuppression (neutropenia 26% Grade 3/4, thrombocytopenia 18%; primary G-CSF cycles 2+ if prior Grade 4, transfusion thresholds Hb<8/plt<25k)
Cardiotoxicity (3-9% angina/MI; baseline ECHO/troponin, hold for symptoms, cardiology evaluation)
DPD deficiency syndrome (mucositis/encephalopathy; permanent discontinuation, hemodialysis if renal failure)

Patient Management and Practical Recommendations

Prospective DPD screening via DPYD genotyping (*2A, *13, c.1905+1G>A, c.2846A>T) or uracil breath/enzyme tests identifies at-risk patients; comprehensive toxicity prophylaxis enhances tolerability.

Pre-treatment Tests

DPYD pharmacogenomic testing or DPD phenotyping (mandatory per CPIC/EMA guidelines)
Renal function (CrCl ≥30 mL/min required), LFTs, CBC/differential/platelets, pregnancy test (teratogenic)
Cardiac evaluation (ECG/ECHO if prior fluoropyrimidines), HBV/HCV serology, urinalysis

Precautions During Treatment

Weekly CBC/electrolytes/LFTs cycles 1-2, then biweekly; daily patient-reported HFS/diarrhea logs
Strict warfarin avoidance (weekly INR x4); no allopurinol/phenytoin (toxicity potentiation)
24/7 oncology hotline; caregiver dose administration verification

Do’s and Don’ts

Do administer tablets whole within 30 minutes after low-fat meal (enhances AUC 25%)
Do apply thick emollients/10% urea cream BID to palms/soles starting pretreatment
Don’t crush/chew/dissolve tablets; report diarrhea >4/day, HFS pain/blisters immediately
Don’t use folate supplements, dental procedures during cycles 1-2

Legal Disclaimer

This guide provides general information about capecitabine and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations. Treatment decisions should consider individual patient factors, and this content does not endorse any specific therapy.